Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

The role of radiotherapy in MPNST and the impact of NF1 status on outcomes: Insights from a multicenter cohort study
Jansma, Christianne Y. M. N. , Grünhagen, Dirk J. , Flucke, Uta , Slooff, Willem‐Bart M., Dalen, Thijs van , Been, Lukas B. , Bonenkamp, Han J. , Anten, Monique , Broen, Martinus P. G. , Bemelmans, Marc H.A., Bramer, Jos A. M. , Schaap, Gerard R. , Hage, Jos A. van der , Pendleton, Courtney , Spinner, Robert J. , Erasmus, Coert Frederik , Taal, Walter , Martin, Enrico , Coert, J Henk , Verhoef, Cornelis , Taal, Walter , Grünhagen, Dirk J , Kievit, Arthur J. , Houdt, Winan J. van , Sande, Michiel A. J. van de , Coert, J. Henk , Verhoef, Cornelis

Neuro-Oncology | August 5, 2025 | Volume: 27 | Issue: 12 | Pages: 3214-3223

10.1093/neuonc/noaf186 | PMID 40795877 Get It

Abstract Background Malignant peripheral nerve sheath tumors (MPNSTs) are rare, aggressive sarcomas, with 40% associated with neurofibromatosis type 1 (NF1). Surgical excision is the main treatment for localized disease; however, local recurrence (LR) remains high. Radiotherapy (RTx) is increasingly used to enhance local control in STS, but its use remains controversial due to the potential for increased major wound complications and an increased risk of secondary malignancies in NF1 patients. This study investigated the use and impact of RTx on local control in MPNSTs, particularly in the NF1 setting. Methods Surgically treated primary MPNSTs from 1988 to 2019 in the MONACO multicenter cohort were included. Differences in demographics, treatment, and RTx use between NF1 and non-NF1 cases were examined. Factors influencing RTx administration and LR were assessed via multivariable analyses. Results Among 499 patients (33.1% NF1), 143 (28.7%) experienced LRs. Radiotherapy was administered to 56.3% of patients (57.0% in the NF1 group), with 27.3% receiving neoadjuvant and 72.7% adjuvant RTx. RTx was administered significantly more often to high-grade and extremity tumors. While RTx did not affect overall survival, it reduced LR risk in sporadic cases (hazard ratio [HR] 0.530; 95% confidence interval [CI], 0.354–0.793) but not in the NF1 subgroup (HR 1.00; 95% CI, 0.545–1.85). In NF1 patients, a microscopically positive margin (R1) was the only risk factor for LR development (HR 2.1; 95% CI, 1.19–3.79). Conclusions RTx is frequently used in the treatment of MPNSTs, regardless of NF1 status. While it may affect the LR rate in sporadic cases, its impact on NF1 patients is less clear.
The Intersection of Menopause and Epilepsy: A Review of Current Knowledge and Gaps
Latt, Thazin, Alkhaldi, Modhi , Puntambekar, Preeti , Sheth, Anumeha, Conner, Kelly , Ortiz‐Guerrero, Gloria , Snehal, Isha , Krishnaiengar, Suparna, Mihaylova, Temenuzhka , Moore‐Hill, Debra , Norton, Anna , Ortiz-Guerrero, Gloria , Voinescu, P. Emanuela , Smith, Kelsey M. , Zarroli, Katherine A. , Pegg, Emily , Decker, Barbara , Blank, Leah J. , Bromley, Rebecca , Cavitt, Jennifer , Norton, Anna, Bui, Esther , Vadlamudi, Lata

EMJ Neurology | August 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.33590/emjneurol/jpeb4231 Get It

While hormonal changes have been recognised to influence seizure control and have been studied in association with menstrual cycles and pregnancy, there is a paucity of data on the menopause transition in epilepsy. Given the known effects of sex steroid hormones on neuronal excitability, their endogenous fluctuations during perimenopause, as well as menopause hormone treatments, may alter seizure control. Epilepsy may also be associated with premature ovarian insufficiency and early menopause. This is especially important for epilepsy-related comorbidities, for which menopause can constitute a second hit, such as osteoporosis. Additional considerations for females with epilepsy across the menopause continuum include changes in antiseizure medication clearance and potential interactions with menopausal hormone therapy or other concomitant medications. This comprehensive review summarises the currently available literature on epilepsy and menopause, highlights gaps in knowledge, and underscores the need for research efforts, particularly longitudinal studies investigating the menopause transition.
CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis
Kambhampati, Swetha , Ahn, Kwang Woo , Patel, Jinalben , Lian, Qinghua, Hertzberg, Mark P. , Metheny, Leland , Hong, Sanghee , Jain, Tania , Aljurf, Mahmoud, Vaughn, John L. , Wirk, Baldeep , Manjappa, Shivaprasad , Oliver, Carolina , Mohty, Razan , Hamadani, Mehdi, Herrera, Alex F. , Thiruvengadam, Swetha Kambhampati , Epperla, Narendranath , Jain, Tania , Iqbal, Madiha , Wirk, Baldeep , Oliver, Carolina , Shadman, Mazyar , Herrera, Alex F , Hertzberg, Mark, Epperla, Narendranath , Aljurf, Mahmoud , Beitinjaneh, Amer , Gopal, Ajay K. , Iqbal, Madiha , Shadman, Mazyar , Turtle, Cameron J. , Hamadani, Mehdi

American Journal of Hematology | August 5, 2025 | Volume: 100 | Issue: 10 | Pages: 1803-1812

10.1002/ajh.70027 | PMID 40762207 Get It

ABSTRACT Transformed follicular lymphoma (tFL) is typically associated with chemotherapy resistance and a poor prognosis. There are limited data regarding outcomes after CD19‐directed chimeric antigen receptor T‐cell (CAR T) therapy in relapsed/refractory (R/R) tFL. A total of 923 adult patients with R/R tFL who received commercial CD19 CAR T therapy between 2017 and 2023 were identified in the Center for International Blood and Marrow Transplant Research registry. Median age was 64 years (range: 30–86) and median prior lines of therapy was 4 (range: 1–18). Most patients (78%) received axicabtagene ciloleucel, with 67% of patients having resistant disease at the time of CAR T infusion. At a median follow‐up of 25 months (range: 1–72) from CAR T infusion, the 2‐year overall survival (OS) was 57% (95% CI: 53–60) and progression‐free survival (PFS) was 43% (95% CI: 40–47). The 2‐year cumulative incidences of relapse or progression (rel/prog) and non‐relapse mortality (NRM) were 47% (95% CI: 44–51) and 9% (95% CI: 7–11), respectively. The overall response rate to CAR T was 76%, with a complete response rate of 63%. Grade ≥ 3 cytokine release syndrome (CRS) was observed in 7.1% and grade ≥ 3 immune effector cell–associated neurologic syndrome (ICANS) in 21.6% of patients. Multivariable analysis suggested that resistant disease status at the time of CAR T, use of bridging therapy, and high comorbidity index ≥ 3 were associated with inferior PFS and OS. Older age ≥ 60 significantly increased the risk of NRM. Our study suggests that CD19 CAR T is effective and safe for tFL.
Circuit mechanisms of GPe pauses account for adaptive exploration
Song, Minryung , Kang, Shinwoo , Yang, Minsu Abel , Choi, Doo‐Sup , Lee, Sang Wan , Song, Minryung , Yang, Minsu Abel , Choi, Doo-Sup

No container title available | August 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7117998/v1 | PMID 40799737 Get It

Abstract The external globus pallidus (GPe) has traditionally been viewed as a relay nucleus within the basal ganglia (BG), but accumulating evidence indicates a more dynamic role in reinforcement learning (RL). One key characteristic of GPe activity—transient pauses in high-frequency discharge (HFD) neurons—is preserved across species, yet its potential implications in RL remains unclear. Here, we developed a neurophysiologically grounded computational model to investigate the origin and role of GPe pauses in RL. Our model successfully replicated a range of empirical observations, including pause dynamics during learning and cue-related activity modulation. We demonstrated that the GPe-subthalamic nucleus (STN) circuit functions analogously to a denoising autoencoder, modulating baseline excitability in downstream BG circuits and that GPe pauses emerge as circuit-level consequences of strong, convergent inhibition from the GPe to STN. Simulations and in vivo recordings revealed that the activity of GPe-STN projecting neurons increases following sudden environmental changes, promoting adaptive exploration by disrupting action value contrast. Intriguingly, this same configuration impairs performance with extended training, suggesting that habitual behavior may benefit from weakened GPe-to-STN projections. These findings provide a unifying framework for understanding GPe pause dynamics and highlight circuit-level distinctions supporting the balance between flexibility and proficiency in RL.
Comparative Outcomes of Intra-Aortic Balloon Pump Versus Percutaneous Left Ventricular Assist Device in High-Risk Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
Sivasubramanian, Dhiran , Senthilkumar, Virushnee, Palanisamy, Nithish Nanda, Bilgaiyan, Rashi, Aravind, Smrti , Kumar, Sri Drishaal, Balasubramanian, Aishwarya , Sanil, Sathwik , Balasubramanian, Karthick, Kamaladasan, Dharssini, Pilathodan, Hashwin, Shankar, Kiruba, Nanda Palanisamy, Nithish , Kumar, Sri Drishaal, Balasubramanian, Aishwarya

Journal of Clinical Medicine | August 5, 2025 | Volume: 14 | Issue: 15 | Pages: 5430

10.3390/jcm14155430 | PMID 40807051 Get It

Background/Objectives: High-risk percutaneous coronary interventions (HR-PCIs) often require mechanical circulatory support (MCS) to maintain hemodynamic stability. Intra-aortic balloon pump (IABP) and percutaneous left ventricular assist device (PLVAD) are two commonly used MCS devices that differ in their mechanisms. We aimed to evaluate and compare the clinical outcomes associated with IABP and PLVAD use in HR-PCIs without cardiogenic shock. Methods: We conducted a search of PubMed, Scopus, Cochrane, Mendeley, Web of Science, and Embase to identify relevant randomized controlled trials and cohort studies, and we included 13 studies for the systematic review and meta-analysis. The primary goal was to define the difference in early mortality (in-hospital and 30-day mortality), major bleeding, and major adverse cardiovascular event (MACE) components (cardiogenic shock, acute kidney injury (AKI), and stroke/TIA) in IABP and PLVAD. We used a random-effects model with the Mantel–Haenszel statistical method to estimate odds ratios (ORs) and 95% confidence intervals. Results: Among 1 trial and 12 cohort studies (35,554 patients; 30,351 IABP and 5203 PLVAD), HR-PCI with IABP was associated with a higher risk of early mortality (OR = 1.53, 95% CI [1.21, 1.94]) and cardiogenic shock (OR = 2.56, 95% CI [1.98, 3.33]) when compared to PLVAD. No significant differences were found in the rates of arrhythmia, major bleeding, AKI, stroke/TIA, or hospital length of stay. Conclusions: In high-risk PCIs, PLVAD use is associated with lower early mortality and cardiogenic shock risk compared to IABP, with no significant differences in other major outcomes.
Prolonged Water‐Only Fasting Followed by a Whole‐Plant‐Food Diet Promotes Fat‐Free Mass Recovery and Continued Fat Mass Loss in Adults With Overweight or Obesity
Gabriel, Sahmla , Ncube, Mackson, Goldman, David , Goldhamer, Alan , Myers, Toshia R. , Myers, Toshia R , Scharf, Eugene

Obesity Science & Practice | August 5, 2025 | Volume: 11 | Issue: 4 | Pages: No page available

10.1002/osp4.70086 | PMID 40765844 Get It

ABSTRACTIntroductionConventional weight‐loss strategies often result in inadequate fat loss, poor sustainability, and unintended lean mass loss. Prolonged water‐only fasting followed by dietary change may offer an effective alternative, but its impact on body composition remains underexplored.MethodsThis secondary analysis utilized dual‐energy X‐ray absorptiometry (DXA) to assess changes in fat‐free mass (FFM), fat mass (FM), and bone mineral content (BMC) in adults [median (IQR) age: 62 (15) years with overweight or obesity. Participants underwent a median (IQR) of 14 (6) days of water‐only fasting, followed by 6 (3) days of food reintroduction with a whole‐plant‐food diet and a subsequent maintenance period of 45 (5) days. Study visits occurred at baseline and at the end of each period.ResultsAt end of fasting, FFM accounted for 74% of total BW lost during fasting. However, at the follow‐up visit, the median (IQR) percentage change in total BW, FFM, FM, and visceral adipose tissue (VAT) mass from baseline was −8.2 (5.2), −4.4 (5.6), −14.7 (8.9), −15.8 (12.8) %, respectively. At follow‐up, FM loss accounted for 67% of the total BW lost. BMC remained unchanged across all study visits.ConclusionsThis protocol produced sustained FM loss, specifically VAT mass, and FFM recovery, suggesting it may support effective weight management.
Targeted Quantitation of Phosphotyrosine‐Containing Proteins in T‐Cell Receptor Signaling Using a SureQuant‐Based Mass Spectrometry Approach
Bhat, Firdous Ahmad , Ding, Husheng, Peterson, Jane A., Charlesworth, Mary Cristine, Kandasamy, Richard K. , Pandey, Akhilesh , Bhat, Firdous A., Pandey, Akhilesh , Kandasamy, Richard K , Mun, Dong‐Gi , Peterson, Jane A.

PROTEOMICS | August 5, 2025 | Volume: 25 | Issue: 16 | Pages: 40-47

10.1002/pmic.70023 | PMID 40862336 Get It

ABSTRACT T‐cell receptor (TCR) signaling plays a crucial role in various biological processes and is usually studied using global mass spectrometry‐based phosphoproteomic studies. Despite advancements in targeted mass spectrometry‐based assays for protein quantification, their application in studying signaling processes, for example, reproducible measurements of post‐translational modifications (PTMs) such as phosphorylation, remains limited. Tyrosine phosphorylation is critical for many signaling pathways but presents challenges due to the low abundance of phosphotyrosine‐containing peptides. Conventional untargeted methods often encounter data gaps when analyzing large sample sets, particularly for low‐abundance peptides. To address this issue, a targeted proteomics method called “SureQuant” was employed, which relies on triggered data acquisition with heavy isotope‐labeled peptides. This method has been shown to provide sensitive and reproducible quantification of low‐abundance peptides. Here we describe the development of a SureQuant‐based method to quantify phosphotyrosine peptides that are involved in the TCR signaling pathway. To monitor the change in phosphotyrosine signals upon activation, the T‐cells were stimulated with anti‐CD3/CD28 antibodies. We successfully quantified changes in important phosphotyrosine peptides in primary T‐cells upon stimulation with anti‐CD3/CD28 antibodies. This study showcases the ability of the SureQuant approach to accurately quantify low‐abundance phosphotyrosine peptides, highlighting its broader potential to study a diverse set of PTMs in physiological or clinical settings. Summary T‐cell receptor (TCR) signaling plays a fundamental role in immune responses, regulating T‐cell activation, differentiation, and function. While tyrosine phosphorylation is a key regulatory mechanism in this pathway, the low abundance of phosphotyrosine peptides presents a major challenge for their detection and quantification in complex biological samples. By employing the SureQuant targeted mass spectrometry approach, we achieved highly sensitive and reproducible quantification of key phosphotyrosine sites involved in T‐cell activation. This study provides a systematic view of TCR signaling dynamics, revealing distinct phosphorylation patterns across different activation timepoints. Our findings demonstrate the effectiveness of SureQuant in quantifying low‐abundance, post‐translationally modified peptides, offering a valuable tool for studying signaling pathways with greater precision. Additionally, this methodological framework can be extended to investigate other signaling networks, immune cell functions, and disease‐associated phosphotyrosine modifications.
Informed Consent Practices in Anesthesiology: A National Survey of Informed Consent Preferences and Perceptions Among Practicing Anesthesiologists
Nelson, Niesa, Reno, Annieka, Gray, Spencer, Drugge, Elizabeth , Ayar, Jay, Medow, Marvin S. , Tanious, Mariah K. , Eriator, Ike, Baker, E. Brooke , Ramanujan, Krishnan S. , Weber, Garret , Nelson, Niesa, Gray, Spencer, Saynhalath, Rita

International Anesthesiology Clinics | August 5, 2025 | Volume: 63 | Issue: 4 | Pages: 18-25

10.1097/aia.0000000000000491 | PMID 40760968 Get It

Flawed Benchmarks and Biased Cohorts: Reassessing the Evidence for CP ‐ GEP (Merlin) Versus 31‐ GEP (
Bellomo, Domenico , Gross, Christian, Pazhava, Ani , Perniciaro, Charles , Dwarkasing, Jvalini, Meves, Alexander , Gross, Christian

International Journal of Dermatology | August 5, 2025 | Volume: 65 | Issue: 1 | Pages: 12-14

10.1111/ijd.70000 | PMID 40761084 Get It

Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives
Carrillo, Marı́a C., Chen, Christopher , Choi, Seong Hye , Fontana, Igor C. , Graff‐Radford, Jonathan, Heidebrink, Judith L. , Hu, Chaur‐Jong , Ihara, Ryoko , Ip, Fanny C.F., Fitri, Fasihah Irfani , Jack, Clifford R. , Yoon, Soo Jin , Jia, Jianping , Kandiah, Nagaendran, Kowa, Hisatomo , Joie, Renaud La , Noritake, Ryoji, Okonkwo, Ozioma C. , Raman, Rema , Shen, Yong , Simuni, Tanya, Snyder, Heather M. , Sriwannopas, Orapitchaya, Wang, Huali , Zhou, Jin , Sexton, Claire E. , Carrillo, María C. , Simuni, Tanya , Chen, Christopher , Mahinrad, Simin , Jack, Clifford R , La Joie, Renaud , Simuni, Tanya , Iwatsubo, Takeshi , Sperling, Reisa Anne , Algeciras‐Schimnich, Alicia , Arai, Hidenori , Barron, Anna M. , Benzinger, Tammie L.S. , Graff‐Radford, Jonathan , Grill, Joshua D. , Ikeuchi, Takeshi , Iwata, Atsushi , Kandiah, Nagaendran , Kim, SangYun , Niimi, Yoshiki , Palmqvist, Sebastian , Rafii, Michael S. , Stoeckel, Luke E. , Flier, Wiesje M. van der , Wilcock, Donna M. , Zetterberg, Henrik , Mahinrad, Simin

Alzheimer's & Dementia | August 5, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70536 | PMID 40760693 Get It

Abstract The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease‐modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment‐induced changes in disease biology. These frameworks enable opportunities for personalized interventions—encompassing pharmacological and non‐pharmacological strategies—and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker‐based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. Highlights Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic‐specific impacts, focusing on Asia.